CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 44 enrolled
Drug / intervention
Efprezimod alfa +3 moredrug
Likely dose
Placebo 100 mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02663622
NCT02663622Phase 2Completed
CompareCT.gov

A Phase II Trial of CD24Fc for Prevention of Acute Graft-versus-Host Disease Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplant

Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)·interventional·Posted Jan 26, 2016·Updated Jan 23, 2024

In Brief

A Phase 2 clinical trial evaluating Efprezimod alfa, Methotrexate, and 2 other interventions for Graft Versus Host Disease and 2 related conditions. Completed, enrolled 44 participants across 4 sites.

Detailed Summary

This is a multicenter prospective phase IIa dose escalation and phase IIa expansion cohort clinical trial designed to evaluate the safety and tolerability of efprezimod alfa for acute GVHD prophylaxis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGraft Versus Host Disease, Hematopoietic Stem Cell Transplantation, Leukemia
CountriesUnited States
CollaboratorsOhio State University, University of Michigan Rogel Cancer Center, Indiana University, Barbara Ann Karmanos Cancer Institute, National Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJan 26, 2016
Enrollment StartSep 19, 2016
Primary CompletionJun 8, 2020
Study CompletionMay 18, 2021
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 10.4 years ago

Interventions

Efprezimod alfadrug

Acute GVHD prophylaxis

Methotrexatedrug

Acute GVHD prophylaxis

Tacrolimusdrug

Acute GVHD prophylaxis

Placebodrug

100 ml saline IV infusion.